Evidence map›Paper›PMID 36506338›Full record

ArticleJournal of asthma and allergy2022

Subgroup Analysis of a Randomized Trial of the Effects of Positive Messaging on Patient-Reported Outcomes with Asthma - Effect of Obesity.

Anne M Mathews, Isaretta Riley, Robert Henderson, Janet T Holbrook, Jason E Lang, Anne E Dixon, Robert A Wise, Loretta G Que

Open access · goldAbstract read
In one paragraph

Article in Journal of asthma and allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Anne M MathewsDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC, USA.
Isaretta RileyDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC, USA.
Robert HendersonDepartment of Epidemiology, Johns Hopkins Center for Clinical Trials and Evidence Synthesis, Baltimore, MD, USA.
Janet T HolbrookDepartment of Epidemiology, Johns Hopkins Center for Clinical Trials and Evidence Synthesis, Baltimore, MD, USA.
Jason E LangDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC, USA.
Anne E DixonDepartment of Medicine, Division of Pulmonary Disease and Critical Care Medicine, University of Vermont, Burlington, VT, USA.
Robert A WiseDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-8353-2349
Loretta G QueDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Duke University, Durham, NC, USA.ORCID 0000-0001-9188-9244
Duke University · USJohns Hopkins University · USUniversity of Vermont · US

Funding

Coping with Asthma through Life Management (CALM)K01HL159043 · NHLBI · DUKE UNIVERSITY · PI RILEY, ISARETTA · 2021 to 2025
$808k
NHLBI NIH HHS K01 HL159043
6 · The paper itself

Abstract

Objective: Asthma in obese patients represents a specific phenotype that is associated with increased symptoms, more frequent and severe exacerbations, reduced responsiveness to treatment, and decreased quality of life. Marketing and placebos have been shown to alter subjective responses to interventions in both asthma and obesity. We evaluated obesity as a potential treatment effect modifier of the effects enhanced drug messaging or placebos on subjective asthma outcomes. Methods: We conducted a secondary analysis of a multicenter, randomized clinical trial that studied the effect of messaging and placebos on asthma outcomes. A total of 601 participants were randomized (1:1:1:1:1) to one of 5 groups: enhanced messaging with montelukast or placebo, neutral messaging with montelukast or placebo, or usual care and followed for 4 weeks after randomization. We compared baseline characteristics by obesity status for 600 participants with data on body weight. Obesity was evaluated as an effect modifier for enhanced messaging (versus neutral messaging) and on placebo effects (versus usual care) in 362 participants assigned to a placebo group or usual care for three asthma questionnaires: Asthma Control Questionnaire, Asthma Quality of Life Questionnaire and Asthma Symptoms Utility Index. Results: Overall, 227 (37%) of participants were obese. Obese participants were older (mean age 41 vs 34), more likely female (82% vs 67%) and self-identified as Black (44% vs 25%) than non-obese participants. As previously published, enhanced messaging was associated with improvements in patient-reported asthma scores, but there was no evidence for a placebo effect. Obesity status did not influence the message effects nor did it modify responses to placebo. Conclusion: Obesity has been shown to be an important factor associated with asthma outcomes and an effect modifier of drug treatment effects. We conducted a post hoc, subgroup analysis of data from a multicenter randomized trial of enhanced messaging and placebo associated with drug treatment on asthma outcomes. Our findings suggest that observed differences in treatment effects between obese and non-obese patients sometimes seen in trials of asthma treatments are unlikely to be due to different "placebo" effects of treatment and may reflect differential physiologic effects of active agents.

Indexed as

asthmaasthma questionnairesmessagingobesity

Identifiers

PMID36506338
PMCPMC9733563
OpenAlexW4310716552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.